Vident Investment Advisory LLC lifted its stake in Inovio Pharmaceuticals Inc (NASDAQ:INO) by 95.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 291,713 shares of the biopharmaceutical company’s stock after buying an additional 142,328 shares during the period. Vident Investment Advisory LLC’s holdings in Inovio Pharmaceuticals were worth $1,205,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Teachers Advisors LLC lifted its stake in shares of Inovio Pharmaceuticals by 11.2% in the fourth quarter. Teachers Advisors LLC now owns 159,972 shares of the biopharmaceutical company’s stock valued at $661,000 after buying an additional 16,104 shares during the period. Deutsche Bank AG lifted its stake in shares of Inovio Pharmaceuticals by 247.7% in the fourth quarter. Deutsche Bank AG now owns 449,708 shares of the biopharmaceutical company’s stock valued at $1,856,000 after buying an additional 320,376 shares during the period. Tocqueville Asset Management L.P. bought a new stake in shares of Inovio Pharmaceuticals in the fourth quarter valued at about $218,000. Renaissance Technologies LLC bought a new position in Inovio Pharmaceuticals during the fourth quarter worth about $1,503,000. Finally, Geode Capital Management LLC increased its holdings in shares of Inovio Pharmaceuticals by 10.5% during the fourth quarter. Geode Capital Management LLC now owns 833,627 shares of the biopharmaceutical company’s stock worth $3,442,000 after buying an additional 79,001 shares in the last quarter. Institutional investors and hedge funds own 31.64% of the company’s stock.

How to Become a New Pot Stock Millionaire

Inovio Pharmaceuticals stock opened at $5.10 on Thursday. The firm has a market cap of $452.02, a price-to-earnings ratio of -4.72 and a beta of 2.55. Inovio Pharmaceuticals Inc has a 52-week low of $3.76 and a 52-week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.06. The business had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $9.13 million. Inovio Pharmaceuticals had a negative net margin of 208.92% and a negative return on equity of 66.07%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.35) EPS. equities analysts anticipate that Inovio Pharmaceuticals Inc will post -1.07 EPS for the current fiscal year.

Several research firms have recently weighed in on INO. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Royal Bank of Canada raised their price target on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, March 15th. Maxim Group set a $8.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, March 15th. BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Finally, ValuEngine lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $19.07.

COPYRIGHT VIOLATION NOTICE: “Vident Investment Advisory LLC Grows Position in Inovio Pharmaceuticals Inc (INO)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/vident-investment-advisory-llc-grows-position-in-inovio-pharmaceuticals-inc-ino/1957410.html.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals Inc (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.